Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy
Authors
Keywords
Indoleamine 2,3- dioxygenase (IDO), IDO inhibitor, Immunotherapy, Nanomedicine, Combined therapy
Journal
BIOMATERIALS
Volume 276, Issue -, Pages 121018
Publisher
Elsevier BV
Online
2021-07-12
DOI
10.1016/j.biomaterials.2021.121018
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tailor‐Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma
- (2021) Xi Hu et al. Advanced Science
- A Smart Multifunctional Nanoparticle for Enhanced Near-Infrared Image-Guided Photothermal Therapy Against Gastric Cancer
- (2021) Jun Shao et al. International Journal of Nanomedicine
- Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
- (2021) Shuyang S. Qin et al. Cells
- Near-Infrared Photothermal/Photodynamic-in-One Agents Integrated with a Guanidinium-Based Covalent Organic Framework for Intelligent Targeted Imaging-Guided Precision Chemo/PTT/PDT Sterilization
- (2021) Yu-Shi Liu et al. ACS Applied Materials & Interfaces
- Dynamic nanoassembly-based drug delivery system (DNDDS): Learning from nature
- (2021) Xi Hu et al. ADVANCED DRUG DELIVERY REVIEWS
- Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy
- (2020) Yijia Liu et al. BIOMATERIALS
- Mechanism of indoleamine 2, 3‐dioxygenase inhibiting cardiac allograft rejection in mice
- (2020) Chuan Li et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
- (2020) John D. Martin et al. Nature Reviews Clinical Oncology
- Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1
- (2020) Sean Hacking et al. PATHOLOGY RESEARCH AND PRACTICE
- Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer
- (2020) Xianli Hu et al. Advanced Science
- Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
- (2020) Filippo Galli et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Cancer nanomedicine meets immunotherapy: opportunities and challenges
- (2020) Qingxue Sun et al. ACTA PHARMACOLOGICA SINICA
- The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
- (2020) Yuanyuan Zhang et al. Cellular & Molecular Immunology
- Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer
- (2020) Lijuan Wei et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer
- (2020) Fengyun Shen et al. BIOMATERIALS
- Recent advances in targeted nanomedicine as promising antitumor therapeutics
- (2020) Siddhanth Hejmady et al. DRUG DISCOVERY TODAY
- Drug Delivery Systems of Natural Products in Oncology
- (2020) Marisa Colone et al. MOLECULES
- TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
- (2020) Francesco Manfredi et al. Frontiers in Immunology
- Biologically Modified Nanoparticles as Theranostic Bionanomaterials
- (2020) Jielai Yang et al. PROGRESS IN MATERIALS SCIENCE
- Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine
- (2020) Ying Wang et al. Bioactive Materials
- Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
- (2019) Geoffrey T. Gibney et al. Journal for ImmunoTherapy of Cancer
- BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).
- (2019) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- Biomimetic Metal-Organic Framework Nanoparticles for Cooperatively Combination of Antiangiogenesis and Photodynamic Therapy for Enhanced Efficacy
- (2019) Huan Min et al. ADVANCED MATERIALS
- Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
- (2019) Takahiro Ebata et al. INVESTIGATIONAL NEW DRUGS
- Multifunctional Nanoregulator Reshapes Immune Microenvironment and Enhances Immune Memory for Tumor Immunotherapy
- (2019) Meng Yu et al. Advanced Science
- Cold to Hot: Rational Design of a Minimalist Multifunctional Photo-immunotherapy Nanoplatform toward Boosting Immunotherapy Capability
- (2019) Di Zhang et al. ACS Applied Materials & Interfaces
- Self‐Amplified Drug Delivery with Light‐Inducible Nanocargoes to Enhance Cancer Immunotherapy
- (2019) Bing Feng et al. ADVANCED MATERIALS
- Pembrolizumab in lung cancer: current evidence and future perspectives
- (2019) Giuliano Palumbo et al. Future Oncology
- Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)
- (2019) Ute F. Röhrig et al. JOURNAL OF MEDICINAL CHEMISTRY
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Echoes of a failure: what lessons can we learn?
- (2019) Vernon K Sondak et al. LANCET ONCOLOGY
- A Three-in-One Immunotherapy Nanoweapon via Cascade-Amplifying Cancer-Immunity Cycle against Tumor Metastasis, Relapse, and Postsurgical Regrowth
- (2019) Qian Li et al. NANO LETTERS
- Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway
- (2019) Dechun Liu et al. NANO LETTERS
- Platelet-Mimicking Biotaxis Targeting Vasculature-Disrupted Tumors for Cascade Amplification of Hypoxia-Sensitive Therapy
- (2019) Mingkang Zhang et al. ACS Nano
- RBC membrane camouflaged prussian blue nanoparticles for gamabutolin loading and combined chemo/photothermal therapy of breast cancer
- (2019) Bin Liu et al. BIOMATERIALS
- Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
- (2019) Xuexiang Han et al. BIOMATERIALS
- The therapeutic potential of targeting tryptophan catabolism in cancer
- (2019) Christiane A. Opitz et al. BRITISH JOURNAL OF CANCER
- Nanoparticle-mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
- (2018) Xiaopin Duan et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy
- (2018) Sarah Yentz et al. BIODRUGS
- Organic molecule-based photothermal agents: an expanding photothermal therapy universe
- (2018) Hyo Sung Jung et al. CHEMICAL SOCIETY REVIEWS
- A patent review of IDO1 inhibitors for cancer
- (2018) Jae Eun Cheong et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Renal-Clearable Hollow Bismuth Subcarbonate Nanotubes for Tumor Targeted Computed Tomography Imaging and Chemoradiotherapy
- (2018) Xi Hu et al. NANO LETTERS
- A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
- (2018) Hatem Soliman et al. Oncotarget
- Biological Stimulus-Driven Assembly/Disassembly of Functional Nanoparticles for Targeted Delivery, Controlled Activation, and Bioelimination
- (2018) Xi Hu et al. Advanced Healthcare Materials
- Advanced smart-photosensitizers for more effective cancer treatment
- (2018) Wooram Park et al. Biomaterials Science
- Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and Immunotherapy
- (2018) Jinrong Peng et al. Advanced Science
- Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
- (2018) Asha Nayak-Kapoor et al. Journal for ImmunoTherapy of Cancer
- Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment
- (2018) Bing Feng et al. ADVANCED MATERIALS
- Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment
- (2018) Da Hye Kim et al. BIOMATERIALS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non–small cell lung cancer (mNSCLC).
- (2018) Rina Hui et al. JOURNAL OF CLINICAL ONCOLOGY
- Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
- (2018) Adil Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.
- (2018) Yousef Zakharia et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the IDO1 pathway in cancer: from bench to bedside
- (2018) Ming Liu et al. Journal of Hematology & Oncology
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
- (2018) Alexander J. Muller et al. Seminars in Immunopathology
- Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
- (2018) Eric Fox et al. Frontiers in Oncology
- Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity
- (2018) Mengmeng Yan et al. ACS Applied Materials & Interfaces
- Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway
- (2018) Jianqin Lu et al. ACS Nano
- Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence
- (2018) Biagio Ricciuti et al. PHARMACOLOGY & THERAPEUTICS
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- (2017) Lieve Brochez et al. EUROPEAN JOURNAL OF CANCER
- A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
- (2017) Rebecca Kristeleit et al. GYNECOLOGIC ONCOLOGY
- New Epigallocatechin Gallate (EGCG) Nanocomplexes Co-Assembled with 3-Mercapto-1-Hexanol and β-Lactoglobulin for Improvement of Antitumor Activity
- (2017) Yuanyuan Yang et al. Journal of Biomedical Nanotechnology
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- PDCT-06. RADIO-IMMUNOTHERAPY USING THE IDO-INHIBITOR INDOXIMOD IN COMBINATION WITH RE-IRRADIATION FOR CHILDREN WITH PROGRESSIVE BRAIN TUMORS IN THE PHASE 1 SETTING: AN UPDATED REPORT OF SAFETY AND TOLERABILITY (NCT02502708)
- (2017) Theodore S Johnson et al. NEURO-ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors
- (2017) Bilal Zulfiqar et al. OncoTargets and Therapy
- Enhanced radiosensitizing by sodium glycididazole in a recurrent esophageal carcinoma tumor model
- (2017) Peipei Wu et al. Oncotarget
- Immune Checkpoint Inhibitors: Basics and Challenges
- (2017) Bin Li et al. CURRENT MEDICINAL CHEMISTRY
- Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors
- (2016) Yanqi Ye et al. ACS Nano
- Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy
- (2016) Xiao Zhao et al. BIOMATERIALS
- Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies
- (2016) A. M. Monjazeb et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
- (2016) Senthamil R. Selvan et al. CURRENT CANCER DRUG TARGETS
- Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.
- (2016) Nathan Bahary et al. JOURNAL OF CLINICAL ONCOLOGY
- Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies
- (2016) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A multi-functional nanoplatform for tumor synergistic phototherapy
- (2016) Huijuan Zhang et al. NANOTECHNOLOGY
- An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
- (2016) Yichao Chen et al. Nature Communications
- Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
- (2016) Qian Chen et al. Nature Communications
- A phase I study of indoximod in patients with advanced malignancies
- (2016) Hatem H. Soliman et al. Oncotarget
- Analysis of nanoparticle delivery to tumours
- (2016) Stefan Wilhelm et al. Nature Reviews Materials
- Physical Chemistry of Nanomedicine: Understanding the Complex Behaviors of Nanoparticles in Vivo
- (2015) Lucas A. Lane et al. Annual Review of Physical Chemistry
- The Immune System in Cancer Prevention, Development and Therapy
- (2015) Serge M. Candeias et al. Anti-Cancer Agents in Medicinal Chemistry
- Development of individualized anti-metastasis strategies by engineering nanomedicines
- (2015) Qianjun He et al. CHEMICAL SOCIETY REVIEWS
- A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer
- (2015) Niroshaathevi Arumuggam et al. PHYTOTHERAPY RESEARCH
- Targeting the indoleamine 2,3-dioxygenase pathway in cancer
- (2015) Yong Wha Moon et al. Journal for ImmunoTherapy of Cancer
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
- (2015) Hatem H. Soliman et al. Oncotarget
- Combinatorial Photothermal and Immuno Cancer Therapy Using Chitosan-Coated Hollow Copper Sulfide Nanoparticles
- (2014) Liangran Guo et al. ACS Nano
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- DNA methylation impairs TLR9 induced Foxp3 expression by attenuating IRF-7 binding activity in fulminant type 1 diabetes
- (2013) Zhen Wang et al. JOURNAL OF AUTOIMMUNITY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lignans from Carthamus tinctorius suppress tryptophan breakdown via indoleamine 2,3-dioxygenase
- (2013) Susanne Kuehnl et al. PHYTOMEDICINE
- Indoleamine 2,3-Dioxygenase and Dendritic Cell Tolerogenicity
- (2012) Jamie L Harden et al. IMMUNOLOGICAL INVESTIGATIONS
- (-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells
- (2012) KENGO OGAWA et al. Oncology Letters
- CpG plus radiotherapy: a review of preclinical works leading to clinical trial
- (2012) Kathy A. Mason et al. Frontiers in Oncology
- Drug-loaded polyelectrolyte microcapsules for sustained targeting of cancer cells
- (2011) Viviana Vergaro et al. ADVANCED DRUG DELIVERY REVIEWS
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
- (2011) J. Godin-Ethier et al. CLINICAL CANCER RESEARCH
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
- (2010) Jonathan P. Celli et al. CHEMICAL REVIEWS
- Sonication-Assisted Synthesis of Polyelectrolyte-Coated Curcumin Nanoparticles
- (2010) Zhiguo Zheng et al. LANGMUIR
- Converting Poorly Soluble Materials into Stable Aqueous Nanocolloids
- (2010) Yuri M. Lvov et al. LANGMUIR
- Indoleamine 2,3-Dioxygenase Tissue Distribution and Cellular Localization in Mice: Implications for Its Biological Functions
- (2009) Xiangchen Dai et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells
- (2009) B. Baban et al. JOURNAL OF IMMUNOLOGY
- Adjuvant role for cell death during chemo- and radiotherapy of cancer?
- (2007) Patrizia Rovere-Querini et al. Expert Review of Clinical Immunology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started